SLC9A2 and neoplasm: Unlike Bevacizumab (a humanized IgG1 monoclonal antibody targeting VEGFA), our study indicates that SLC9A2 can inhibit VEGFA synthesis, effectively blocking VEGFA production at its source and serving as a superior target for anti-tumor angiogenesis strategies.